Reply to the Letter to the Editor 'AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma' by Y. Shimazu

Affiliations

• ¹ Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France; Laboratory of Immunomodulators, School of Medicine, Centro de Estudios Farmacológicos y Botánicos (CEFYBO), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), University of Buenos Aires, Buenos Aires, Argentina.
• ² Digestive and Medical Oncology, Paul Brousse Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Saclay, Villejuif, France.
• ³ Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France; Hospital de Alta Complejidad El Cruce, Florencio Varela, Buenos Aires; University Arturo Jauretche, Florencio Varela, Buenos Aires, Argentina. Electronic address: [email protected].
• ⁴ Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes, Marseille, France. Electronic address: [email protected].